OpenAI just expanded its Reinforcement Fine-Tuning Research Program, offering select developers alpha API access to build domain-specific expert models. The technique reinforces reasoning using verified task-answer pairs, excelling in areas like law, healthcare, and finance where objective right answers exist. A public release is slated for early 2025.
Oura just rolled out Symptom Radar, an early-warning feature that flags signs of respiratory illness before symptoms hit. By tracking shifts in resting heart rate, body temperature trends, and breathing rates, the ring alerts users to take it easy. It arrives on Oura Ring Gen 3 and Oura Ring 4 by December 11.
Researchers just introduced BioEmu, a generative AI system that samples thousands of independent protein conformations per hour on a single GPU. Trained on molecular dynamics and stability data, it predicts free energy with errors near 1 kcal/mol. Basically, it brings months of supercomputing simulation down to a few cheap GPU hours.
Neuralink just launched a new feasibility trial called the CONVOY Study, expanding its N1 brain implant to control an investigational assistive robotic arm. The study allows cross-enrollment from its ongoing PRIME Study, marking a key shift from restoring digital freedom to regaining physical mobility.
ChatGPT just outperformed human doctors in a diagnostic study, scoring 90% on medical cases compared to 74% for unassisted physicians. Why it matters: doctors paired with ChatGPT barely improved at 76%, largely because physicians refused to listen when the AI disagreed with them and struggled to leverage its capabilities.
Thrive AI Health just launched an early demo of its AI health coach on its website, but it is currently bare-bones and largely nonfunctional. Backed by the OpenAI Startup Fund and Arianna Huffington, the chat-based tool aims to deliver hyper-personalized wellness advice, though the sub-10-person startup clearly still has a long road ahead.
NVIDIA, the Weizmann Institute, and Pheno.AI just unveiled GluFormer, a transformer-based generative AI model that forecasts glucose levels and health outcomes up to four years in advance. Trained on continuous glucose monitor data, it can also predict how a body reacts to specific foods, opening the door to precision preventive care for diabetes.
XRHealth just launched an AI-powered medical XR platform designed to tailor immersive treatment environments for patients. Clinicians can use its AI Generator Space to build custom 360-degree scenes and dynamic avatars, backed by AI-driven session analysis and treatment recommendations across physical rehab and mental health.
Google DeepMind just released the software code for its protein-folding model AlphaFold 3 for non-commercial scientific research. The release follows six months of academic backlash over withholding the code, though accessing the actual model weights still requires an application request.
University of Tokyo researchers just demonstrated an AI system that screens for high blood pressure and diabetes using a brief 5-to-30-second video of your face and palm. It analyzes micro-changes in skin blood flow with up to 94% accuracy for hypertension and 75% for diabetes, completely skipping cuffs and needles. Why it matters: If miniaturized into smartphones, contactless daily health checkups could finally become a reality.
Researchers just revealed that OpenAI’s Whisper transcription model frequently hallucinates, with a University of Michigan study finding fabricated text in 80% of reviewed transcripts. Other engineers found widespread inventions, including fictional medical treatments. Why it matters: Whisper is already widely deployed across medical consultations and enterprise cloud platforms.
Biotech startup Iambic Therapeutics just unveiled Enchant, a multimodal transformer model designed to predict how drug candidates behave in humans from the earliest discovery phases. By pairing abundant lab data with tiny amounts of clinical trial data, it sets a new state-of-the-art benchmark for predicting human drug half-life and aims to eliminate years of risky preclinical R&D.
Harvard Medical School researchers just launched TxGNN, the first AI model specifically built to repurpose existing medicines for rare and untreated conditions. It evaluated nearly 8,000 drugs across 17,080 diseases, beating rival models by roughly 50% while explaining its clinical reasoning. The tool is free for clinicians.
Meta just revealed the winners of its inaugural Llama Impact Innovation Awards, awarding organizations across Africa, the Middle East, Asia Pacific, and Latin America up to $35,000 in funding and matching ad credits. The recognized projects leverage Llama models for local challenges, including bilingual medical diagnosis, vaccine education, and low-cost vision aids.
Biotech firm Genmab just expanded ChatGPT Enterprise across its entire organization, issuing over 2,000 licenses under its "AI Everywhere" initiative. Teams built over 100 custom GPTs to draft clinical trial documents and translate research, reporting an average time savings of 3.5 hours weekly. Why it matters: It shows frontier LLMs moving past generic productivity into complex, regulated biotech workflows.
Researchers just developed AINU, an AI model that differentiates cancer cells from normal cells and spots viral infections within an hour of entering a cell. By analyzing super-resolution microscopy snapshots down to 20 nanometers, it acts like facial recognition for the nucleus. Why it matters: It could give doctors a massive head start on diagnoses, though expensive lab equipment currently limits clinical rollout.
Researchers at USC just used machine learning to solve a deadly medical puzzle: reprogramming glioblastoma cells into immune-activating dendritic cells. By turning the cancer cells into antigen-presenting guides inside the tumor, the method bypasses the blood-brain barrier and boosted mouse survival rates by up to 75% alongside immunotherapy. Why it matters: It offers a biological Trojan horse against one of humanity's deadliest cancers.
Tech-loaded "AI toothbrushes" from giants like P&G, Colgate, and Philips might not actually improve your oral health, according to an Ars Technica investigation. Instead, the embedded sensors and companion apps serve as a direct pipeline for brands to capture real-world brushing habits, feed internal R&D, and pitch personalized product ads. Why it matters: The AI hype wave has officially entered your bathroom, and your daily hygiene routine is now prime behavioral data.
The IOC's Olympic AI Agenda is seeing its first real-world test at the 2024 Paris Olympics. AI tools are assisting coaches with real-time motion analysis and injury prevention, supporting gymnastics judging, and automatically scrubbing abusive social media posts directed at athletes. Why it matters: Elite sports are treating AI not just as a training shortcut, but as infrastructure for competitive fairness and athlete safety.
Samsung just launched the Galaxy Ring, its first-ever smart ring priced at $399 with a battery life of up to seven days. The lightweight titanium device uses Galaxy AI to analyze biometrics and deliver personalized daily health scores. Why it matters: unlike market leader Oura, it requires no monthly subscription fee.
